Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overview-Reference-Cited by-同舟云学术

Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overview

Published:2023-03-24 Issue:12 Volume:39 Page:1603-1612
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Lasala Ruggero¹,Zovi Andrea²,Isgrò Valentina³,Romagnoli Alessia⁴,Musicco Felice⁵,Santoleri Fiorenzo⁶

Affiliation:

1. Hospital Pharmacy of Corato, Local Health Unit of Bari, Italy

2. Ministry of Health, Ministero della Salute, Rome, Italy

3. Clinical Pharmacy, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), Palermo, Italy

4. Territorial Pharmaceutical Service, Local Health Unit of Lanciano Vasto Chieti, Chieti, Italy

5. Hospital Pharmacy, IRCCS Regina Elena National Cancer Institute, Rome, Italy

6. Hospital Pharmacy, Pescara Hospital, Pescara, Italy

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2023.2192610

Reference26 articles.

1. The biology and management of non-small cell lung cancer

2. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer;Rosell R;Semin Oncol,1998

3. Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

4. Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing

5. Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC;Immunotherapy;2024-09-13

2. A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer in Italy;Journal of Oncology Pharmacy Practice;2024-03-27

3. Guest editor foreword: real-world evidence and medical affairs;Current Medical Research and Opinion;2023-12-02

4. Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease Progression;Cancers;2023-07-18